Based on this YouTube video's total view count of 3.58M views and industry-standard rates, the estimated total earning is $2.51K - $7.17K through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Ozempic is a game-changer. Here’s how it works. with 3,587,147 views, 48,445 likes, and 2,761 comments. Experience the impact of this video content that has captured audience attention.

This diabetes drug could be the future of weight management. Subscribe and turn on notifications 🔔 so you don't miss any videos: http://goo.gl/0bsAjO Ozempic, a medication developed to manage type 2 diabetes, has been in the news a lot lately because of one of its signature side effects: drastic weight loss. Both Ozempic and Wegovy, Ozempic’s counterpart approved specifically for weight loss by the FDA, are brand names of a drug called semaglutide. Semaglutide is one of several drugs that mimics a crucial digestive hormone called glucagon-like peptide 1, or GLP-1. It amplifies a process our bodies perform naturally. GLP-1 is released in our intestines when we eat, and there are receptors for the hormone in cells all over the body. In the pancreas, GLP-1 promotes the production of insulin and suppresses the production of glucagon. This helps insulin-resistant bodies, like those with type 2 diabetes or obesity, manage blood sugar levels. In the stomach, GLP-1 slows gastric emptying, extending the feeling of being full. In the brain, GLP-1 suppresses appetite, which also promotes satiety and curbs hunger, so we eat less. In late 2022, a rush to use Ozempic off-label for weight loss, likely prompted by its sudden rise in popularity in social media, led to a shortage of the drug for people who need it. But more drugs like semaglutide are currently in the process of being approved by the FDA to be prescribed for weight loss, likely signaling an end to the shortage and a promising new generation of medical treatment of obesity. Further reading: Mila Clarke's YouTube channel: https://www.youtube.com/TheHangryWoman The New Obesity Breakthrough Drugs, by Eric Topol https://erictopol.substack.com/p/the-new-obesity-breakthrough-drugs The Discovery and Development of Liraglutide and Semaglutide, by Lotte Bjerre Knudsen and Jesper Lau https://www.frontiersin.org/articles/10.3389/fendo.2019.00155/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Endocrinology&id=440904 The pregnancy risks of Ozempic and Wegovy need more attention, Julia Belluz writes for Vox. Read more here: https://bit.ly/41znHCv Note: The headline on this piece has been updated. Previous headline: The game-changing weight loss drug, explained Make sure you never miss behind-the-scenes content in the Vox Video newsletter, sign up here: http://vox.com/video-newsletter Vox.com is a news website that helps you cut through the noise and understand what's really driving the events in the headlines. Check out http://www.vox.com Support Vox's reporting with a one-time or recurring contribution: http://vox.com/contribute-now Shop the Vox merch store: http://vox.com/store Watch our full video catalog: http://goo.gl/IZONyE Follow Vox on Facebook: http://facebook.com/vox Follow Vox on Twitter: http://twitter.com/voxdotcom Follow Vox on TikTok: http://tiktok.com/@voxdotcom

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.